Celldex Therapeutics, Inc. Share Price Today: Live Updates & Key Insights

Celldex Therapeutics, Inc. share price today is $31.03, up 2.9%. The stock opened at $30.1 against the previous close of $30.03, with an intraday high of $31.81 and low of $30.01.

Celldex Therapeutics, Inc. Share Price Chart

Celldex Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Celldex Therapeutics, Inc. Share Price Performance

$31.03 0.029(2.9%) CLDX at 23 Mar 2026 12:28 PM Biotechnology
Lowest Today 30.01
Highest Today 31.81
Today’s Open 30.1
Prev. Close 30.03
52 Week High 31.99
52 Week Low 14.40
Day’s Range: Low 30.01 High 31.81
52-Week Range: Low 14.40 High 31.99
1 day return -
1 Week return +2.35
1 month return +27.06
3 month return +13.02
6 month return +24.1
1 year return +48.65
3 year return -15.02
5 year return +18.1
10 year return -

Celldex Therapeutics, Inc. Institutional Holdings

Wellington Management Company LLP 12.14

Kynam Capital Management, LP 8.93

BlackRock Inc 8.27

FMR Inc 7.37

Vanguard Health Care Inv 6.38

Vanguard Group Inc 6.05

Point72 Asset Management, L.P. 5.85

Bellevue Group AG 5.43

BB Biotech AG Ord 5.34

State Street Corp 4.27

COMMODORE CAPITAL LP 3.85

T. Rowe Price Associates, Inc. 3.58

Vanguard Total Stock Mkt Idx Inv 3.19

Deep Track Capital, LP 3.00

State Street® SPDR® S&P® Biotech ETF 2.88

BRAIDWELL LP 2.79

Eventide Asset Management, LLC 2.47

Geode Capital Management, LLC 2.45

iShares Russell 2000 ETF 2.38

Millennium Management LLC 1.82

Novo A/S 1.80

Vestal Point Capital LP 1.75

Eversept Partners, LP 1.73

Vanguard Explorer Inv 1.59

Eventide Healthcare & Life Sciences I 1.56

The Goldman Sachs Group Inc 1.55

Polar Capital Holdings PLC 1.51

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Fidelity Small Cap Index 0.97

Pictet-Biotech P USD 0.93

Eventide Gilead N 0.90

iShares Russell 2000 Value ETF 0.85

American Century Small Cap Growth Inv 0.84

American Century U.S. Small Cap Growth 0.84

Strategic Advisers Fidelity US TtlStk 0.83

FIAM Small Cap Core Composite 0.81

US Small-Cap Growth II Equity Comp 0.81

T. Rowe Price New Horizons 0.81

FIAM Small Cap Core CIT Cl B 0.80

Fidelity Stock Selector Small Cap 0.78

Celldex Therapeutics, Inc. Market Status

Strong Buy: 10

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Celldex Therapeutics, Inc. Fundamentals

Market Cap 2056.90 M

PB Ratio 3.792

PE Ratio 0.0

Enterprise Value 1482.75 M

Total Assets 582.98 M

Volume 3242637

Celldex Therapeutics, Inc. Company Financials

Annual Revenue FY25:1500000 1.5M, FY23:4365000 4.4M, FY22:2357000 2.4M, FY21:4651000 4.7M, FY20:7418000 7.4M

Annual Profit FY25:1500000 1.5M, FY23:null 0.0M, FY22:2357000 2.4M, FY21:4651000 4.7M, FY20:7418000 7.4M

Annual Net worth FY25:-258800000 -258.8M, FY23:-124610000 -124.6M, FY22:-122783000 -122.8M, FY21:-70511000 -70.5M, FY20:-59780000 -59.8M

Quarterly Revenue Q4/2025:75000 0.1M, Q3/2025:0 0.0M, Q2/2025:730000 0.7M, Q1/2025:695000 0.7M, Q3/2024:3191000 3.2M

Quarterly Profit Q4/2025:75000 0.1M, Q3/2025:-62931000 -62.9M, Q2/2025:730000 0.7M, Q1/2025:695000 0.7M, Q3/2024:3191000 3.2M

Quarterly Net worth Q4/2025:-81360000 -81.4M, Q3/2025:-67044000 -67.0M, Q2/2025:-56600000 -56.6M, Q1/2025:-53796000 -53.8M, Q3/2024:-42121000 -42.1M

About Celldex Therapeutics, Inc. & investment objective

Company Information Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Organisation Biotechnology

Employees 198

Industry Biotechnology

CEO Mr. Anthony S. Marucci M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Celldex Therapeutics, Inc. FAQs

What is the share price of Celldex Therapeutics, Inc. today?

The current share price of Celldex Therapeutics, Inc. is $31.03.

Can I buy Celldex Therapeutics, Inc. shares in India?

Yes, Indian investors can buy Celldex Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Celldex Therapeutics, Inc. shares in India?

You can easily invest in Celldex Therapeutics, Inc. shares from India by:

Can I buy fractional shares of Celldex Therapeutics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Celldex Therapeutics, Inc.?

Celldex Therapeutics, Inc. has a market cap of $2056.90 M.

In which sector does Celldex Therapeutics, Inc. belong?

Celldex Therapeutics, Inc. operates in the Biotechnology sector.

What documents are required to invest in Celldex Therapeutics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Celldex Therapeutics, Inc.?

The PE ratio of Celldex Therapeutics, Inc. is N/A and the PB ratio is 3.79.